Traditionally regarded as an anti-insulin hormone, glucagon was soon employed in clinical practice to treat insulin-induced hypoglycemic coma in individuals with type 1 diabetes mellitus (T1DM). This evidence concerns the gene GCG and type 1 diabetes mellitus.